It seems that weight loss will likely be very important for the benefits of the GLP-1 medicines in some conditions, and much less important, or not at all essential, for benefits in other disorders. According to Lane, although GLP-1 receptor agonists show promise in reducing cardiovascular risk factors, long-term cardiovascular safety trials are needed to assess cardiovascular mortality and events
Al-Madhagy S, Ashmawy NS, Mamdouh A, Eldahshan OA, Farag MA
Individuals with upregulated CYP450 2E1, such as alcoholics, are particularly vulnerable to liver failure from APAP use [7, 8]
fixed-duration BT The stepped-care approach represents a fundamental shift from conventional treatment protocols by customizing interventions based on milestone completion
Patel et al., Vitamins, Amino Acids, and Drugs and Formulations Used in Nutrition, 2016, pp
Zheng H, Chen Q, Chen M, Wu X, She T-W, Li J, et al